Keratoconjunctivitis Sicca
63
0
0
55
Key Insights
Highlights
Success Rate
98% trial completion (above average)
Published Results
28 trials with published results (44%)
Research Maturity
55 completed trials (87% of total)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
1.6%
1 terminated out of 63 trials
98.2%
+11.7% vs benchmark
35%
22 trials in Phase 3/4
51%
28 of 55 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 55 completed trials
Clinical Trials (63)
Tolerability and Efficacy Study of Reinnerva/Lubristil+G vs Vismed
Levocarnitine for Dry Eye in Sjogren's Syndrome
A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease
Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya
Goblet Cell Response and Dry Eye Symptoms After PRK and LASIK
A Randomized Study of Smile Exercise for Dry Eye
Pilot Study to Investigate the Feasibility, Reliability and Efficacy of Utilizing OCT to Automate PROSE Fitting
Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B
Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
Differential Diagnosis of Sjögren's Versus Non-Sjögren's Dry Eye
Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Trial of CF101 to Treat Patients With Dry Eye Disease
Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca
Ocular Manifestations in Rheumatic Diseases
Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome
An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Tear Production by Nasal Neurostimulation Compared to Active Control
Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)
Treatment of Dry Eye Disease Using Pro-ocular™ - A Proof of Concept, Safety, and Efficacy Study